Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Mol Cell Neurosci ; 94: 41-51, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30529228

RESUMO

α-Melanocyte stimulating hormone (α-MSH) is a melanocortin which exerts potent anti-inflammatory and anti-apoptotic effects. Melanocortin 4 receptors (MC4R) are abundantly expressed in the brain and we previously demonstrated that [Nle(4), D-Phe(7)]melanocyte-stimulating hormone (NDP-MSH), an α-MSH analogue, increased expression of brain derived-neurotrophic factor (BDNF), and peroxisome proliferator-activated receptor-γ (PPAR-γ). We hypothesized that melanocortins could affect striatal cell survival through BDNF and PPAR-γ. First, we determined the expression of these factors in the striatum. Acute intraperitoneal administration (0.5 mg/kg) of α-MSH increased the levels of BDNF mRNA in rat striatum but not in rat cerebral cortex. Also, protein expression of PPAR-γ and MC4R was increased by acute treatment with α-MSH in striatum but not in cortex. No changes were observed by 48 h treatment. Next, we evaluated melanocortins effect on neuron and glial survival. 3-nitropropionic acid (3-NP), which is known to induce striatal degeneration, was used to induce cell death in the rat striatal cell line ST14A expressing mutant human huntingtin (Q120) or in ST14A cells expressing normal human huntingtin (Q15), in primary cultured astrocytes, and in BV2 cells. NDP-MSH protected Q15 cells, astrocytes and BV2 cells from death by 3-NP whereas it did not fully protect Q120 cells. Protection of Q15 cells and astrocytes was blocked by a MC4R specific inhibitor (JKC-363) and a PPAR-γ antagonist (GW9662). The BDNF receptor antagonist (ANA-12) abolished NDP-MSH protective effect in astrocytes but not in Q15 cells. We demonstrate for the first time that melanocortins, acting through PPAR-γ and BDNF, protect neurons and glial cells from 3-NP toxicity.


Assuntos
Astrócitos/efeitos dos fármacos , Neuroglia/efeitos dos fármacos , Neurônios/efeitos dos fármacos , Nitrocompostos/farmacologia , Propionatos/farmacologia , Receptor Tipo 4 de Melanocortina/metabolismo , Animais , Fator Neurotrófico Derivado do Encéfalo/metabolismo , Hormônios Estimuladores de Melanócitos/efeitos dos fármacos , Ratos Wistar
2.
J Med Chem ; 58(16): 6359-67, 2015 Aug 27.
Artigo em Inglês | MEDLINE | ID: mdl-26218460

RESUMO

Human melanocortin receptors (hMCRs) have been challenging targets to develop ligands that are explicitly selective for each of their subtypes. To modulate the conformational preferences of the melanocortin ligands and improve the biofunctional agonist/antagonist activities and selectivities, we have applied a backbone N-methylation approach on Ac-Nle-c[Asp-His-D-Nal(2')-Arg-Trp-Lys]-NH2 (Ac-Nle(4)-c[Asp(5),D-Nal(2')(7),Lys(10)]-NH2), a nonselective cyclic peptide antagonist at hMC3R and hMC4R and an agonist at hMC1R and hMC5R. Systematic N-methylated derivatives of Ac-Nle(4)-c[Asp(5),D-Nal(2')(7),Lys(10)]-NH2, with all possible backbone N-methylation combinations, have been synthesized and examined for their binding and functional activities toward melanocortin receptor subtypes 1, 3, 4, and 5 (hMCRs). Several N-methylated analogues are selective and potent agonists or antagonists for hMC1R or hMC5R or have selective antagonist activity for hMC3R. The selective hMC1R ligands show strong binding for human melanoma cells. We have also discovered the first universal antagonist (compound 19) for all subtypes of hMCRs.


Assuntos
Hormônios Estimuladores de Melanócitos/efeitos dos fármacos , Receptores de Melanocortina/efeitos dos fármacos , Inibidores de Adenilil Ciclases , Sequência de Aminoácidos , Linhagem Celular Tumoral , Humanos , Ligantes , Melanoma/tratamento farmacológico , Melanoma/patologia , Conformação Molecular , Dados de Sequência Molecular , Relação Estrutura-Atividade
4.
Neurosci Lett ; 423(2): 153-7, 2007 Aug 16.
Artigo em Inglês | MEDLINE | ID: mdl-17693022

RESUMO

Although the orexigenic action of peptide hormones such as ghrelin and growth hormone releasing peptide is different between chickens and mammals, the anorexigenic action of peptide hormones is similar in both species. For example, central administration of peptide hormones such as leptin, cholecystokinin or glucagon has been shown to suppress food intake behavior in chickens and mammals. Central administration of insulin suppresses food intake in mammals. However, the anorexigenic action of insulin in chickens has not yet been identified. In the present study, we investigated the effects of central administration of insulin on food intake in chicks. Intracerebroventricular administration of insulin in chicks significantly suppressed food intake. Central administration of insulin significantly upregulated mRNA levels of proopiomelanocortin (POMC), cocaine- and amphetamine-regulated transcript (CART) and corticotropin-releasing factor (CRF), but did not influence mRNA levels of neuropeptide Y and agouti-related protein in the hypothalamus. These results suggest that alpha-melanocyte stimulating hormone (alpha-MSH, an anorexigenic peptide from the post-translational cleavage of POMC), CART and CRF are involved in the anorexigenic action of insulin in chicks. Furthermore, central administration of alpha-MSH or CART significantly suppressed food intake. In addition, alpha-MSH significantly upregulated CRF mRNA expression, suggesting that the anorexigenic action of alpha-MSH is mediated by CRF. Our findings demonstrate that insulin functions in chicks as an appetite-suppressive peptide in the central nervous system and suggest that this anorexigenic action is mediated by CART, alpha-MSH and CRF.


Assuntos
Regulação do Apetite/fisiologia , Encéfalo/efeitos dos fármacos , Ingestão de Alimentos/efeitos dos fármacos , Insulina/administração & dosagem , Animais , Animais Recém-Nascidos , Encéfalo/fisiologia , Galinhas , Hormônio Liberador da Corticotropina/biossíntese , Hormônio Liberador da Corticotropina/efeitos dos fármacos , Relação Dose-Resposta a Droga , Injeções Intraventriculares , Masculino , Hormônios Estimuladores de Melanócitos/biossíntese , Hormônios Estimuladores de Melanócitos/efeitos dos fármacos , Proteínas do Tecido Nervoso/biossíntese , Proteínas do Tecido Nervoso/efeitos dos fármacos , Pró-Opiomelanocortina/biossíntese , Pró-Opiomelanocortina/efeitos dos fármacos , RNA Mensageiro/análise , Reação em Cadeia da Polimerase Via Transcriptase Reversa
5.
Brain Res Bull ; 55(6): 767-74, 2001 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-11595361

RESUMO

The effect of neonatal treatment with monosodium L-glutamate (MSG) on the dopaminergic systems of the medial basal hypothalamus has been investigated using tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC) immunocytochemistry. Changes in plasma levels of prolactin (PRL) and alpha-melanocyte-stimulating hormone (MSH) have also been determined in intact and in MSG-treated rats after inhibition of TH by alpha-methyl-p-tyrosine (alpha-MpT) or without inhibition of enzyme activity. Monosodium glutamate resulted in a 40% reduction in the number of TH immunopositive tuberoinfundibular neurons, but no change in the number of AADC-positive tuberoinfundibular nerve cells, indicating that this reduction has occurred mainly in TH-positive but AADC-negative elements, i.e., in L-DOPA-ergic neurons. In contrast, MSG did not cause changes in the number of TH and AADC immunoreactive neurons of the periventriculohypophysial and tuberohypophysial dopaminergic systems, and it did not influence basal plasma PRL levels. alpha-methyl-p-tyrosine has increased plasma PRL concentrations in both control and MSG-treated rats of both sexes, but significantly higher responses were detected in females. None of the treatments had any effect on plasma MSH level. These findings suggest that MSG affects primarily L-DOPA-ergic neurons located in the ventrolateral part of the arcuate nucleus, but not dopaminergic neurons situated in the dorsomedial part of the arcuate nucleus; neither PRL nor MSH secretion is altered by MSG; a significant sex difference exists in the pituitary PRL response to inhibition of TH, and this response is not affected by MSG.


Assuntos
Núcleo Arqueado do Hipotálamo/efeitos dos fármacos , Dopamina/metabolismo , Levodopa/metabolismo , Hormônios Estimuladores de Melanócitos/efeitos dos fármacos , Neurônios/efeitos dos fármacos , Prolactina/efeitos dos fármacos , Glutamato de Sódio/farmacologia , Animais , Animais Recém-Nascidos/anatomia & histologia , Animais Recém-Nascidos/crescimento & desenvolvimento , Animais Recém-Nascidos/metabolismo , Núcleo Arqueado do Hipotálamo/enzimologia , Núcleo Arqueado do Hipotálamo/crescimento & desenvolvimento , Descarboxilases de Aminoácido-L-Aromático/metabolismo , Contagem de Células , Inibidores Enzimáticos/farmacologia , Feminino , Imuno-Histoquímica , Masculino , Hormônios Estimuladores de Melanócitos/sangue , Hormônios Estimuladores de Melanócitos/metabolismo , Neurônios/enzimologia , Neurônios/metabolismo , Neurotoxinas/farmacologia , Prolactina/sangue , Prolactina/metabolismo , Ratos , Ratos Sprague-Dawley , Reprodução/efeitos dos fármacos , Reprodução/fisiologia , Caracteres Sexuais , Tirosina 3-Mono-Oxigenase/antagonistas & inibidores , Tirosina 3-Mono-Oxigenase/metabolismo , alfa-Metiltirosina/farmacologia
6.
Brain Res Bull ; 51(6): 479-84, 2000 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-10758337

RESUMO

Some rat melanotrophs express in vivo tyrosine hydroxylase mRNA. In this report we show, by Western-blotting, that cultures of adult rat melanotrophs, but not adenohypophyseal cells, express tyrosine hydroxylase. Immunocytochemical analyses confirmed the existence of a subpopulation of melanotrophs expressing tyrosine hydroxylase. Bromocryptine (2.5 x 10(-7) M), a D2 dopamine agonist, down-regulated melanotroph tyrosine hydroxylase expression in a time-dependent manner; initial effect was detected at 15 h and maximum at 3 days treatment (reduction to about 40% of control values). Down-regulation at 3 days was dose-dependent (ED(50) around 2 x 10(-9) M). This decrease was reversed by sulpiride, a D2 dopamine antagonist. The cell number was slightly increased by bromocryptine treatment. These data suggest tyrosine hydroxylase expression in melanotrophs being under tonic inhibitory control by dopamine innervation in vivo.


Assuntos
Dopamina/metabolismo , Hormônios Estimuladores de Melanócitos/efeitos dos fármacos , Hormônios Estimuladores de Melanócitos/metabolismo , Hipófise/efeitos dos fármacos , Hipófise/metabolismo , Tirosina 3-Mono-Oxigenase/genética , Tirosina 3-Mono-Oxigenase/metabolismo , Animais , Bromocriptina/farmacologia , Técnicas de Cultura de Células , Agonistas de Dopamina/farmacologia , Imuno-Histoquímica , RNA Mensageiro/efeitos dos fármacos , RNA Mensageiro/metabolismo , Ratos , Ratos Wistar , Fatores de Tempo
7.
Ontogenez ; 24(2): 49-54, 1993.
Artigo em Russo | MEDLINE | ID: mdl-8488012

RESUMO

The activity of melanotropins in pituitary homogenates and blood of Wistar rats obtained from the nursery Stolbovaia (Russian Academy of Medical Sciences) was studied using the method of biological testing (Hogben, Slome, 1931; Golichenkov, 1980). In order to elucidate, to what extent the normal status of melanotropic activity is retained in albino rats, two experimental series were performed. Melanotropic activity was determined in (1) intact rats and (2) in rats receiving subcutaneous injections of parachlorophenylalanine, a specific inhibitor of serotonin synthesis. Melanotropic activity of Wistar rats hypophysis during the studied period of development was similar to that of normal pigmented rats. However, the peak of melanotropic activity of blood which is characteristically observed in pigmented rats on day 3 of postnatal development is absent in the case of Wistar rats. The experimentally induced decrease in the serotonin level did not result in the increased melanotropic activity of blood. These data suggest that certain structures of hypophysis responsible for MSH secretion can be disturbed in Wistar rats. A short-term peak of blood MSH in rats during the first week after birth is known to provide for maturation of dopaminergic neurons located in the arcuate nucleus of the hypothalamus. Consequently, the absence of such peak in Wistar rats should result in neuroendocrine disturbances such as inadequate functioning of dopaminergic neurons responsible for melanotropin secretion by hypophysis beginning from the second week after birth (Lichtensteiger, Schlumpf, 1986).


Assuntos
Hormônios Estimuladores de Melanócitos/metabolismo , Hipófise/metabolismo , Ratos Wistar/metabolismo , Envelhecimento/efeitos dos fármacos , Envelhecimento/metabolismo , Animais , Animais Recém-Nascidos , Fenclonina/farmacologia , Larva , Hormônios Estimuladores de Melanócitos/efeitos dos fármacos , Hormônios Estimuladores de Melanócitos/farmacologia , Hipófise/efeitos dos fármacos , Rana temporaria , Ratos , Ratos Wistar/crescimento & desenvolvimento , Pele/efeitos dos fármacos
8.
Am J Physiol ; 262(1 Pt 2): R77-84, 1992 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-1733342

RESUMO

The objective of this study was to compare the cardiovascular and renal effects of the two gamma-melanocyte-stimulating hormone (MSH) peptide sequences in the pro-opiomelanocortin prohormone structure in conscious, anesthetized, and pithed spontaneous hypertensive rats (SHR) and normotensive Wistar Kyoto (WKY) controls. In the conscious but not in the pithed rats, intravenous injection of gamma 2- and gamma 1-MSH induced a rapid and dose-dependent increase in mean arterial pressure (MAP), and gamma 2-MSH was more potent than gamma 1-MSH. The pressor response was more pronounced and more sustained in the SHR compared with the WKY. There were dose-dependent and significant increases in heart rate (HR) after gamma 2- and gamma 1-MSH in the SHR. At intravenous infusions of low doses of gamma 2-MSH, which did not significantly influence MAP or HR, urinary sodium excretion was significantly increased in both SHR and WKY. In conscious, but not in anesthetized rats, intracerebroventricular administration of the gamma 2-MSH peptide induced sustained increases in MAP in both SHR and WKY. After intrathecal administration, there were transient pressor effects of gamma 2-MSH. We conclude that the pro-opiomelanocortin-derived gamma 2- and gamma 1-MSH peptide sequences possess potent rapid pressor actions. The pressor effects, which require an intact sympathetic nervous system, are more pronounced in the SHR strain. Moreover, gamma 2-MSH induces natriuresis when administered in nonpressor doses in WKY and SHR.


Assuntos
Sistema Cardiovascular/efeitos dos fármacos , Hipertensão/fisiopatologia , Rim/efeitos dos fármacos , Hormônios Estimuladores de Melanócitos/farmacologia , Anestesia , Animais , Estado de Descerebração , Injeções Intravenosas , Injeções Intraventriculares , Injeções Espinhais , Masculino , Hormônios Estimuladores de Melanócitos/efeitos dos fármacos , Ratos , Ratos Endogâmicos SHR , Ratos Endogâmicos WKY , Valores de Referência
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...